Collegium Pharmaceutical (COLL) Enterprise Value (2014 - 2026)

Collegium Pharmaceutical's Enterprise Value history runs 13 years deep, the most recent figure standing at -$288.5 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 45.87% year-over-year to -$288.5 million in Q1 2026; TTM through Mar 2026 was -$288.5 million, a 45.87% decrease from a year earlier, with the FY2025 full-year figure at -$251.1 million, down 54.27% from the prior year.
• Enterprise Value fell to -$288.5 million in Q1 2026 per COLL's latest filing, from -$251.1 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$106.7 million in Q1 2022 and bottomed at -$325.5 million in Q2 2023.
• The 5-year median for Enterprise Value is -$251.1 million (2025), against an average of -$222.4 million.
• Across the five-year window, Enterprise Value sank 165.21% in 2023 and surged 60.61% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$173.7 million in 2022, then tumbled by 78.8% to -$310.5 million in 2023, then jumped by 47.59% to -$162.8 million in 2024, then plunged by 54.27% to -$251.1 million in 2025, then retreated by 14.89% to -$288.5 million in 2026.
• Per Business Quant, the three latest COLL Enterprise Value figures stand at -$288.5 million (Q1 2026), -$251.1 million (Q4 2025), and -$285.9 million (Q3 2025).